Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 550
- 试验地点
- 4
- 主要终点
- to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana
研究概览
简要总结
The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.
详细描述
An atypical akineto-rigid parkinsonian syndrome, unresponsive to L-dopa has been evidenced in Guadeloupe. Abnormally frequent, this progressive supranuclear palsy (PSP)-like syndrome represents a new clinical entity. Unlike in classical PSP 70% of patients have myoclonus, 59% hallucinations, 78% REM sleep behavior disorders. Oculomotor pattern differs from classical PSP suggesting that cortical dysfunction predominates over brainstem impairments. Neuropathological examination in four patients has shown a widespread accumulation of the tau protein in the basal ganglia, the midbrain and cortical areas.
This syndrome has been associated to the regular consumption of food products derived from plants of the Annonaceae family, more specifically Annona Muricata (soursop), suggesting a toxic origin. We have already confirmed the neurotoxic potential of the lipophilic mitochondrial complex I inhibitor annonacin, the major acetogenin in Annona muricata. This class of compounds is specific to Annonaceae. Nanomolar concentrations of annonacin induce the death of dopaminergic neurons in culture, by impairment of energy production. Chronic systemic intoxication of rats with annonacin causes neuronal damage in the same brain regions that are damaged in patients with atypical parkinsonism. These results greatly suggest that the consumption of annonacea might contribute to the pathogenesis of the disease. The H1 subhaplotype in tau gene associated with PSP in Caucasians did not confer risk for PSP-like atypical parkinsonism in Guadeloupe.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
盲法说明
Not masking, 2 groups parallel
入排标准
- 年龄范围
- 19 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Pour les patients :
- •Patient ou tiers responsable ayant reçu une information sur l'étude et ayant signé le consentement éclairé
- •Patient âgé de plus de 18 ans
- •Patient consultant en neurologie ou en gériatrie pour symptomatologie parkinsonienne ou pour troubles cognitifs évocateurs d'une démence à corps de Lewy
- •Patient domicilié aux Antilles-Guyane
- •Pour les témoins :
- •Conjoint ou accompagnant ayant reçu une information sur l'étude et ayant signé le consentement éclairé
- •Personne âgée de plus de 18 ans
- •Personne ne présentant pas de pathologie d'allure neurodégénérative (Parkinson, démence notamment)
- •Personne domiciliée aux Antilles-Guyane
排除标准
- •Pour les patients :
- •Syndrome parkinsonien secondaire (post-traumatique, vasculaire, iatrogène, post encéphalitique)
- •Patient non affilié au régime de sécurité sociale
- •En cas de difficulté de suivi le patient sera exclu de l'étude longitudinale
- •Pour les témoins :
- •Personnes présentant des troubles cognitifs ou un syndrome parkinsonien diagnostiqué.
- •Patient non affilié au régime de sécurité sociale -
研究组 & 干预措施
Patients
Parkinson's patient
干预措施: Clinical and biological exam (Other)
witnesses: without parkinson's disease
Subjects without parkinson's disease
干预措施: Clinical and biological exam (Other)
结局指标
主要结局
to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana
时间窗: At the end of the Period of inclusion, around 5-6 years
Collection of : administrative and socioeconomic data, medical consultation with video recording , recording oculomotor to the atypical
次要结局
- to compare the proportion of atypical forms within parkinsonian syndromes;(At the end of the Period of inclusion, around 5-6 years)
- to characterize the entity "Parkinson-dementia complex" described in Guadeloupe ; to characterize the entity "Parkinson-dementia complex" described in Guadeloupe ;(Through study completion, an average of 11 years)
- to determine the implication of a toxic alimentary factor in the etiopathogenesis of atypical forms and compare the results in the 3 areas (Guadeloupe, Guyane, Martinique);(Through study completion, an average of 11 years)
- to determine the latency of cognitive decline in idiopathic Parkinson's disease in the 3 areas ;(Through study completion, an average of 11 years, post-mortem analysis after death if applicable)
- to constitute a biological collection (plasma, DNA, serum).(At the end of the Period of inclusion, around 5-6 years)
- to determine the natural history of typical and atypical forms of parkinsonism by following a cohort of the incident cases only;(Through study completion, an average of 11 years)
